Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CADL
CADL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CADL News
Candel Therapeutics to Hold Online R&D Event on December 5, 2025
Nov 17 2025
Newsfilter
Citigroup Upholds Buy Rating for Candel Therapeutics (CADL)
Nov 15 2025
NASDAQ.COM
Candel Halts Development of CAN-2409 for Prostate Cancer
Nov 14 2025
SeekingAlpha
Candel Therapeutics Announces Financial Results for Q3 2025 and Key Corporate Updates
Nov 13 2025
Newsfilter
Candel Therapeutics to Showcase at Jefferies Global Healthcare Conference in London
Nov 03 2025
Newsfilter
LifeSci Capital Begins Coverage of Candel Therapeutics with Outperform Rating and Sets Price Target at $16
Oct 21 2025
Benzinga
Candel Therapeutics to Showcase at the 2025 SITC Annual Meeting
Oct 03 2025
Newsfilter
HC Wainwright & Co. Affirms Buy Rating for Candel Therapeutics, Keeps $23 Price Target Intact
Sep 29 2025
Benzinga
Candel Therapeutics Unveils Phase 3 Clinical Trial Results for CAN-2409 in Localized Prostate Cancer at ASTRO 2025
Sep 29 2025
Newsfilter
Candel Therapeutics to Attend Investor Conferences Scheduled for September
Aug 28 2025
Newsfilter
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Jul 24 2025
Newsfilter
ASML, J B Hunt Transport And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Jul 16 2025
Benzinga
HC Wainwright & Co. Assumes Candel Therapeutics at Buy, Announces Price Target of $23
Jun 30 2025
Benzinga
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know
Jun 25 2025
NASDAQ.COM
Candel Therapeutics Announces $15 Mln Direct Offering To Fund CAN-2409 Launch Readiness
Jun 24 2025
NASDAQ.COM
Candel Names Charles Schoch CFO
Jun 23 2025
NASDAQ.COM
Show More News
